PBYI
Price:
$2.25
Market Cap:
$110.36M
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limite...[Read more]
Industry
Biotechnology
IPO Date
2012-04-24
Stock Exchange
NASDAQ
Ticker
PBYI
According to Puma Biotechnology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 11.84. This represents a change of -483.06% compared to the average of -3.09 of the last 4 quarters.
The mean historical PE Ratio of Puma Biotechnology, Inc. over the last ten years is 12.79. The current 11.84 PE Ratio has changed 9.15% with respect to the historical average. Over the past ten years (40 quarters), PBYI's PE Ratio was at its highest in in the June 2020 quarter at 30.29. The PE Ratio was at its lowest in in the September 2022 quarter at -75.00.
Average
12.79
Median
-5.51
Minimum
-40.00
Maximum
207.21
Discovering the peaks and valleys of Puma Biotechnology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 239.76%
Maximum Annual PE Ratio = 207.21
Minimum Annual Increase = -4980.71%
Minimum Annual PE Ratio = -40.00
Year | PE Ratio | Change |
---|---|---|
2023 | 9.45 | -95.44% |
2022 | 207.21 | -4980.71% |
2021 | -4.25 | -37.27% |
2020 | -6.77 | 65.03% |
2019 | -4.10 | -39.67% |
2018 | -6.80 | -45.98% |
2017 | -12.58 | 239.76% |
2016 | -3.70 | -64.81% |
2015 | -10.53 | -73.69% |
2014 | -40.00 | -26.41% |
The current PE Ratio of Puma Biotechnology, Inc. (PBYI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
70.80
5-year avg
40.31
10-year avg
12.79
Puma Biotechnology, Inc.’s PE Ratio is greater than Ultragenyx Pharmaceutical Inc. (-8.17), greater than Crinetics Pharmaceuticals, Inc. (-15.40), greater than Arvinas, Inc. (-5.42), greater than Revolution Medicines, Inc. (-13.31), greater than Kura Oncology, Inc. (-9.19), greater than 2seventy bio, Inc. (-1.47), greater than Intercept Pharmaceuticals, Inc. (-13.55), greater than Iovance Biotherapeutics, Inc. (-6.48), less than Sarepta Therapeutics, Inc. (257.91), greater than Madrigal Pharmaceuticals, Inc. (-10.23), greater than Viking Therapeutics, Inc. (-61.76), greater than Hepion Pharmaceuticals, Inc. (-0.15), greater than PTC Therapeutics, Inc. (-5.05), greater than Heron Therapeutics, Inc. (-5.70), greater than Coherus BioSciences, Inc. (-4.85), greater than Larimar Therapeutics, Inc. (-8.80), greater than MacroGenics, Inc. (-1.49),
Company | PE Ratio | Market cap |
---|---|---|
-8.17 | $5.09B | |
-15.40 | $4.03B | |
-5.42 | $1.68B | |
-13.31 | $6.99B | |
-9.19 | $1.48B | |
-1.47 | $226.59M | |
-13.55 | $794.69M | |
-6.48 | $3.04B | |
257.91 | $12.29B | |
-10.23 | $5.30B | |
-61.76 | $6.00B | |
-0.15 | $4.20M | |
-5.05 | $2.43B | |
-5.70 | $273.00M | |
-4.85 | $142.86M | |
-8.80 | $513.64M | |
-1.49 | $203.85M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Puma Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Puma Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Puma Biotechnology, Inc.'s PE Ratio?
How is the PE Ratio calculated for Puma Biotechnology, Inc. (PBYI)?
What is the highest PE Ratio for Puma Biotechnology, Inc. (PBYI)?
What is the 3-year average PE Ratio for Puma Biotechnology, Inc. (PBYI)?
What is the 5-year average PE Ratio for Puma Biotechnology, Inc. (PBYI)?
How does the current PE Ratio for Puma Biotechnology, Inc. (PBYI) compare to its historical average?